Aclaris Therapeutics, Inc. – NASDAQ:ACRS
Founder-led company
Aclaris Therapeutics stock price today
$1.75
-0.98
-35.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Aclaris Therapeutics stock price monthly change
+106.82%
month
Aclaris Therapeutics stock price quarterly change
+106.82%
quarter
Aclaris Therapeutics stock price yearly change
+157.55%
year
Aclaris Therapeutics key metrics
Market Cap | 214.29M |
Enterprise value | 529.56M |
P/E | -6.15 |
EV/Sales | 17.79 |
EV/EBITDA | -6.14 |
Price/Sales | 19.29 |
Price/Book | 2.90 |
PEG ratio | -0.36 |
EPS | -1.09 |
Revenue | 31.11M |
EBITDA | -122.72M |
Income | -77.26M |
Revenue Q/Q | -5.14% |
Revenue Y/Y | 0.94% |
Profit margin | -292.11% |
Oper. margin | -286.21% |
Gross margin | 59.8% |
EBIT margin | -286.21% |
EBITDA margin | -394.37% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAclaris Therapeutics stock price history
Aclaris Therapeutics stock forecast
Aclaris Therapeutics financial statements
Average Price Target
$6
Potential upside: 242.85%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.86M | -29.56M | -1582.08% |
|---|---|---|---|
| Sep 2023 | 9.28M | -29.26M | -315.24% |
| Dec 2023 | 17.57M | -1.49M | -8.49% |
| Mar 2024 | 2.39M | -16.94M | -706.46% |
| 2023-08-02 | 0.45 | -0.31 |
|---|
| Jun 2023 | 235649000 | 55.89M | 23.72% |
|---|---|---|---|
| Sep 2023 | 218354000 | 62.02M | 28.4% |
| Dec 2023 | 197405000 | 40.22M | 20.38% |
| Mar 2024 | 174065000 | 32.05M | 18.41% |
| Jun 2023 | -20.65M | -19.66M | 26.74M |
|---|---|---|---|
| Sep 2023 | -24.55M | 32.53M | -87K |
| Dec 2023 | -6.76M | 7.55M | 49K |
| Mar 2024 | -20.81M | 16.83M | -55K |
Aclaris Therapeutics alternative data
| Aug 2023 | 100 |
|---|---|
| Sep 2023 | 100 |
| Oct 2023 | 100 |
| Nov 2023 | 100 |
| Dec 2023 | 100 |
| Jan 2024 | 100 |
| Feb 2024 | 100 |
| Mar 2024 | 86 |
| Apr 2024 | 86 |
| May 2024 | 86 |
| Jun 2024 | 86 |
| Jul 2024 | 86 |
Aclaris Therapeutics other data
100.00%
+8.45%
of ACRS is owned by hedge funds
109
-25
59.37M
+3.33M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 14500 | 0 |
| Jun 2024 | 3592200 | 0 |
| Jul 2024 | 888283 | 0 |
| Aug 2024 | 373569 | 0 |
| Nov 2024 | 666666 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | WALKER NEAL director, officer.. | Common Stock | 118,840 | $1.52 | $180,637 | ||
Option | WALKER NEAL director, officer.. | Employee Stock Option (right to buy) | 118,840 | $1.52 | $180,637 | ||
Option | WALKER NEAL director, officer.. | Common Stock | 9,466 | N/A | N/A | ||
Option | WALKER NEAL director, officer.. | Restricted Stock Units | 9,466 | N/A | N/A | ||
Purchase | MEHRA ANAND director | Common Stock | 666,666 | $2.25 | $1,499,999 | ||
Option | WALKER NEAL director, officer.. | Common Stock | 9,467 | N/A | N/A | ||
Option | WALKER NEAL director, officer.. | Restricted Stock Units | 9,467 | N/A | N/A | ||
Option | WALKER NEAL director, officer.. | Common Stock | 9,467 | N/A | N/A | ||
Option | WALKER NEAL director, officer.. | Restricted Stock Units | 9,467 | N/A | N/A | ||
Option | BALTHASER KEVIN officer: Chief Financial Officer | Common Stock | 1,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 23 Nov 2021 Issue date: 28 Jul 2022 |
Application Filling date: 31 Jul 2020 Issue date: 28 Jul 2022 |
Application Filling date: 26 Mar 2021 Issue date: 4 Nov 2021 |
Application Filling date: 16 Mar 2021 Issue date: 16 Sep 2021 |
Grant Utility: Pyrrolopyrimidine ITK inhibitors Filling date: 12 Aug 2019 Issue date: 1 Jun 2021 |
Application Filling date: 23 Jun 2020 Issue date: 13 May 2021 |
Grant Filling date: 2 Nov 2018 Issue date: 20 Apr 2021 |
Application Filling date: 4 May 2020 Issue date: 5 Nov 2020 |
Grant Filling date: 2 Nov 2018 Issue date: 13 Oct 2020 |
Grant Filling date: 24 Apr 2018 Issue date: 4 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2019 25 Feb 2020 | Q4 2019 Earnings Call Transcript |
| Q3 2019 10 Nov 2019 | Q3 2019 Earnings Call Transcript |
Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer
Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch
Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa
Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower
Week In Review: Full-Life Acquires Focus-X And Its 8 Radiotherapeutics In $245 Million Deal
Arena Pharmaceuticals: A Speculative Buy To Play The Upcoming Etrasimod's Data-Readout
-
What's the price of Aclaris Therapeutics stock today?
One share of Aclaris Therapeutics stock can currently be purchased for approximately $1.75.
-
When is Aclaris Therapeutics's next earnings date?
Unfortunately, Aclaris Therapeutics's (ACRS) next earnings date is currently unknown.
-
Does Aclaris Therapeutics pay dividends?
No, Aclaris Therapeutics does not pay dividends.
-
How much money does Aclaris Therapeutics make?
Aclaris Therapeutics has a market capitalization of 214.29M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.03% to 31.25M US dollars. Aclaris Therapeutics made a loss 88.48M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
-
What is Aclaris Therapeutics's stock symbol?
Aclaris Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ACRS".
-
What is Aclaris Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Aclaris Therapeutics?
Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aclaris Therapeutics's key executives?
Aclaris Therapeutics's management team includes the following people:
- Dr. Neal S. Walker D.O. Co-Founder, Chief Executive Officer, Pres & Director(age: 55, pay: $843,530)
- Mr. Frank Ruffo Co-Founder, Chief Financial Officer & Treasurer(age: 59, pay: $581,270)
-
Is Aclaris Therapeutics founder-led company?
Yes, Aclaris Therapeutics is a company led by its founders Dr. Neal S. Walker D.O. and Mr. Frank Ruffo.
-
How many employees does Aclaris Therapeutics have?
As Jul 2024, Aclaris Therapeutics employs 86 workers.
-
When Aclaris Therapeutics went public?
Aclaris Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 6 Oct 2015.
-
What is Aclaris Therapeutics's official website?
The official website for Aclaris Therapeutics is aclaristx.com.
-
Where are Aclaris Therapeutics's headquarters?
Aclaris Therapeutics is headquartered at 640 Lee Road, Wayne, PA.
-
How can i contact Aclaris Therapeutics?
Aclaris Therapeutics's mailing address is 640 Lee Road, Wayne, PA and company can be reached via phone at +48 43247933.
-
What is Aclaris Therapeutics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Aclaris Therapeutics in the last 12 months, the avarage price target is $6. The average price target represents a 242.85% change from the last price of $1.75.
Aclaris Therapeutics company profile:
Aclaris Therapeutics, Inc.
aclaristx.comExchange:
NASDAQ
Full time employees:
86
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
640 Lee Road
Wayne, PA 19087
Wayne, PA 19087
CIK: 0001557746
ISIN: US00461U1051
CUSIP: 00461U105
